Feedback Regulatory News (FDBK)

Trading Update and Director Appointment

· Trading for the financial year ended 31 May 2022 materially ahead of market expectations

· Annemijn Eschauzier joins the Board adding strong healthcare and digital skill sets, as Tim Irish steps down

Feedback plc (AIM: FDBK, "Feedback" or the "Company"), the specialist clinical communication company, is pleased to announce that it has continued its strong momentum into the second half of 2022 and now expects to report revenue for the financial year ended 31 May 2022 materially ahead of market expectations. This follows the previously announced progress with the Company's flagship product Bleepa® and additional technology license fees arising from the Company's partnership with Imaging Engineering LLC (partnership as announced 13 January 2020) booked at the year-end. The Board expects to provide a full 2022 year-end operational and trading update in mid-June 2022.

Appointment of Annemijn Eschauzier to the Board

Annemijn Eschauzier has been appointed to the Board of directors as a Non-Executive Director with immediate effect.

Annemijn brings significant global leadership experience with a career spanning well over 25 years in the Healthcare sector. She started her career at GlaxoSmithKline before moving to GE Healthcare, where she held a variety of leadership positions for over 15 years becoming Chief Marketing Officer Women's Health in September 2017. Since leaving GE Healthcare in March 2021, Annemijn has joined Hardian Health, a company which provides strategic services to navigate the digital health sector. In addition, Annemijn. holds other non-statutory Board member roles and has a bachelor's degree in Dutch Law and Business Administration.

Annemijn will be joining the Board as Tim Irish steps down as NED with immediate effect, after five years with the Company. Tim leaves to pursue new opportunities in the medical sector.

Rory Shaw, Chairman of Feedback, commented: "We are delighted to report that revenue is expected to be materially ahead of expectations. Importantly, we are developing relationships with existing and new partners and believe that we are at an inflection point for growth as we continue to see the benefits of investing the funds raised last year.

"We are delighted to welcome Annemijn to the Board and believe that she will bring a wealth of experience as we steer the Company ever faster towards the commercial growth of our technologies. The Board and I would like to sincerely thank Tim Irish for his fantastic service to the Company over the course of his five years as a NED, we wish him well in all his future endeavours and are delighted that he remains such a strong advocate for the company and our technologies as he goes forward in his new roles"

Anna Marina ("Annemijn") Eschauzier (aged 64) does not currently hold any directorships and has no previous directorships (within 5 years). Annemijn Eschauzier has confirmed that there is no further information to be disclosed pursuant to paragraph (g) of Schedule 2 of the AIM Rules.

Further information on Feedback and its products can be found on the Company's website: https://fbkmed.com/feedback-plc/reports-and-presentations/

Enquiries:

About Feedback

Feedback plc is a specialist clinical communications business, with a mission to improve the efficiency and quality of communications for frontline clinicians and hospitals with a key focus on building solutions that enhance access to high quality patient data.

Feedback has developed a toolkit of clinical communications apps. Its core, regulatory approved product is Bleepa, a revolutionary medical imaging app enabling remote and secure communications between frontline clinicians and teams. CareLocker is an evolutionary GDPR compliant patient-centric cloud architecture - its proprietary technology enables an easy route to creation and mobilisation of individual healthcare records. Bleepa Box is a specialist tool to enable image transfer from remote settings to the Bleepa platform over mobile networks.

The Company has a number of growth opportunities domestically and internationally across a range of markets including the NHS, the veterinary market and private healthcare providers and its highly scalable Software as a Service ("SaaS")-based revenue model is expected to provide increasing levels of visibility as the Company grows its customer base.